Expertos Invitados




Artículos relacionadosArtículos relacionadosArtículos relacionados
Artículos afines de siicsalud publicados en los últimos 4 meses
CANNABIS Y RIESGOS DE TRASTORNOS PSIQUIÁTRICOS
JAMA Psychiatry 80(8):803-810
Difundido en siicsalud: 19 jul 2024
ENDOCANNABINOIDES Y NEURODEGENERACIÓN EN ADULTOS MAYORES
Alzheimer's Research & Therapy 15(154):1-11
Difundido en siicsalud: 14 nov 2024

AVANCES EN EL TRATAMIENTO DEL SINDROME DE TOURETTE

(especial para SIIC © Derechos reservados)
En esta revisión se resumen todos los informes de casos y los ensayos controlados disponibles que investigaron el efecto de diferentes canabinoides en el tratamiento de los tics. También se tuvieron en cuenta las limitaciones y los efectos adversos del tratamiento con estos fármacos.
mullervahl9.jpg Autor:
Kirsten r. Müller-vahl
Columnista Experto de SIIC

Institución:
Department of Clinical Psychiatry, Medical School Hannover

Artículos publicados por Kirsten r. Müller-vahl
Recepción del artículo
24 de Noviembre, 2005 		Aprobación
29 de Diciembre, 2005
Primera edición
30 de Mayo, 2006 		Segunda edición, ampliada y corregida
7 de Junio, 2021

AVANCES EN EL TRATAMIENTO DEL SINDROME DE TOURETTE

Resumen
Los tics son el sello distintivo del síndrome de Tourette (ST). Los antagonistas dopaminérgicos constituyen el tratamiento de elección aunque los neurolépticos frecuentemente presentan efectos colaterales poco satisfactorios. Por tanto, existe un creciente interés en obtener nuevos enfoques terapéuticos. Algunos informes anecdóticos han sugerido que Cannabis sativa podría disminuir los tics. Dos estudios controlados en un número pequeño de pacientes demostraron que el delta-9-tetrahidrocannabinol (THC) -el ingrediente más psicoactivo del cannabis- fue efectivo para controlar los tics sin inducir efectos adversos serios. Además, no se observaron alteraciones del desempeño neuropsicológico. Por lo tanto, el THC debiera incorporarse al listado de fármacos útiles para el tratamiento de los tics. Nosotros recomendamos la utilización de esta molécula en los pacientes con ST que no respondieron al tratamiento con las drogas de referencia o presentaron efectos adversos significativos. Hasta el momento, no queda claro si la planta de cannabis, los agonistas naturales o sintéticos de los receptores cannabinoides o los agentes que interfieren con la inactivación de los endocannabinoides poseen el mejor perfil de efectos adversos en el tratamiento de los tics. Los datos disponibles sugieren que el sistema del receptor cannabinoide central endógeno CB1 podría regular la actividad motora de los ganglios de la base. Por lo tanto, se puede especular que este sistema de receptores podría estar relacionado con la fisiopatología del ST.

Palabras clave
síndrome de Tourette, tics, cannabinoides, marihuana, THC, cannabis


Artículo completo
(castellano)
Extensión:  +/-11.04 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

TETRAHYDROCANNABINOL IN THE TREATMENT OF TICS

Abstract
Tics are the hallmarks of a Tourette syndrome (TS). Dopamine receptor antagonists are the approved treatment, although neuroleptic treatment is often unsatisfactory due to side effects. Therefore, there is expanding interest in new therapeutic strategies. From anecdotal reports it has been suggested that Cannabis sativa L. might reduce tics. Two controlled studies in a small number of TS patients demonstrated that delta-9-tetrahydrocannabinol (THC), the most psychoactive ingredient of cannabis, is effective in the treatment of tics without causing serious adverse effects. In addition, no impairment in neuropsychological performance was observed. Therefore, THC should be added to the list of those drugs that are suitable to reduce tics. We recommend THC treatment in TS patients who did not respond to well-established drugs or develop significant side effects. So far, it is unclear, whether herbal cannabis, other natural or synthetic cannabinoid receptor agonists, or agents that interfere with the inactivation of endocannabinoids may have the best adverse effect profile in the treatment of tics. Available data suggest that the endogenous central cannabinoid CB1 receptor system might regulate motor activity in the basal ganglia. It, therefore, can be speculated that the CB1 receptor system might be involved in the pathophysiology of TS.

Key words
Tourette syndrome, tics, cannabinoids, marijuana, THC, cannabis


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Neurología, Salud Mental
Relacionadas: Farmacología, Medicina Familiar, Medicina Farmacéutica, Medicina Interna, Neurocirugía, Pediatría



Comprar este artículo
Extensión: 11.04 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Kirsten R. Müller-Vahl, Department of Clinical Psychiatry, Medical School Hannover, D-30625, Carl-Neuberg-Str. 1, Hannover, Alemania
Bibliografía del artículo
1. Singer HS. Current issues in Tourette syndrome. Mov Disord 2000; 15(6):1051-1063.
2. Müller-Vahl KR. The treatment of Tourette's syndrome: current opinions. Expert Opin Pharmacother 2002; 3(7):899-914.
3. Sandyk R, Awerbuch G. Marijuana and Tourette's Syndrome. J Clin Psychopharmacol 1988; 8(6):444-445.
4. Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 1993; 7(4):389-391.
5. Müller-Vahl KR, Kolbe H, Schneider U, et al. Cannabinoids: Possible role in pathophysiology of Gilles de la Tourette-syndrome. Acta Psychiat Scand 1998; 98(6):502-506.
6. Müller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of Tourette-Syndrome with delta-9-Tetrahydrocannabinol. Am J Psychiatry 1999; 156(3):495.
7. Müller-Vahl KR, Schneider U, Emrich HM. Combined treatment of Tourette-Syndrome with 9-THC and dopamine receptor antagonists. J Cannabis Therap 2002; 2(3/4):145-154.
8. Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 2002; 35(2):57-61.
9. Müller-Vahl KR, Schneider U, Prevedel H, et al. Delta9-Tetrahydrocannabinol (THC) is Effective in the Treatment of Tics in Tourette Syndrome: a 6-Week Randomized Trial. J Clin Psychiatry 2003; 64(4):459-465.
10. Berding G, Müller-Vahl K, Schneider U, et al. [123I]AM281 SPET imaging of central CB1 receptors before and after D9-THC therapy and whole body scanning for assessment of radiation dose in Tourette patients. J Biol Psy 2004; 55(9):904-915.
11. Berding G, Gielow P, Buchert R, et al. I-124-AM281 PET imaging of central cannabinoid CB1 receptors in a schizophrenic patient. Nuklearmedizin 2005; 44:A122.
12. Fankhauser M. History of cannabis use in western medicine. In: Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Grotenhermen F, Russo E (Eds.), Haworth Press, Binghamton (NY) 2002:37-51.
13. Grotenhermen F. Review of therapeutic effects. In: Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Grotenhermen F, Russo E (Eds.), Haworth Press, Binghamton (NY) 2002: 123-142.
14. Leckman JF, Towbin KE, Ort SI, et al. Clinical assessment of tic disorder severity. In: Tourette's syndrome and tic disorders. Cohen DJ, Bruun RD, Leckman JF (Eds.), John Wiley, New York 1988: 55-78.
15. Moss DE, Montgomery SP, Salo AA, et al. Tetrahydrocannabinol effects on extrapyramidal motor behaviors in an animal model of Parkinson's disease. In: The Cannabinoids: chemical, pharmacologic, and therapeutic aspects. Agurell S, Dewey WL, Willette RE (Eds.), Academic Press, New York 1984: 815-828.
16. Moss DE, Manderscheid PZ, Montgomery SP, et al. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. Life Sci 1989; 44(21):1521-1525.
17. Shapiro AK, Shapiro ES, Young JG, et al. Signs, symptoms, and clinical course. In: Gilles de la Tourette Syndrome. Shapiro AK, Shapiro ES, Young JG, et al. (Eds.), Raven Press, 2nd ed., New York 1988 :127-193.
18. Harcherik DF, Leckman JF, Detlor J, et al. A new instrument for clinical studies of Tourette's syndrome. Am J Acad Child Psychiatry 1984; 23(2):153-160.
19. Müller-Vahl KR, Koblenz A, Jöbges M, et al. Influence of delta-9-Tetrahydrocannabinol (D9-THC) treatment of Tourette-Syndrome on neuropsychological testing. Pharmacopsychiatry 2001; 34(1):19-24.
20. Helmstaedter C, Durwen HF. VLMT. Verbaler Lern- und Merkfähigkeitstest. Schweiz. Arch Neurol Psychiatr 1990; 141(1):21-30.
21. Wechsler D. A standardized memory scale for clinical use. J Psychol 1945; 19:87-95.
22. Wechsler D. Die Messung der Intelligenz Erwachsener. Huber Verlag, Bern,1956.
23. Merz J, Lehrl S, Galster JV, et al. MWT-B - ein Intelligenzkurztest. Psychiatr Neurol Med Psychol 1975; 27(7):423-428.
24. Benton AL. A visual retention test for clinical use. Arch Neurol Psychol 1945; 59:273-291.
25. Swets JA, Green DM, Getty DJ, et al. Signal detection and identification at successive stages of observation. Percept Psychopsy 1978; 23(4):275-289.
26. Arnold W. Der Pauli-Test. Springer, Berlin 1975.
27. Zimmermann P, Fimm B. Neuropsychologische Testbatterie zur Erfassung von Aufmerksamkeitsdefiziten. Psychologisches Institut der Universität Freiburg 1989.
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62.
29. Hamilton M. Development of rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6(4):278-296.
30. Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale - preliminary report. Psychopharmacol Bull 1973; 9(1):13-28.
31. Derogatis LR. SCL 90. Administration, scoring and procedures. Manual-I for the R(evised) version and other instruments of the psychopathology rating scale series. John Hopkins University School of Medicine 1977.
32. Goetz CG, Tanner CM, Wilson RS, et al. A rating scale for Gilles de la Tourette's syndrome: description, reliability, and validity data. Neurology 1987; 37(9):1542-1544.
33. Müller-Vahl KR, Prevedel H, Theloe K, et al. Treatment of Tourette-Syndrome with 9-Tetrahydrocannabinol (D9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 2003; 28(2):384-388.
34. Grotenhermen F. Effects of cannabis and cannabinoids. In: Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Grotenhermen F, Russo E (Eds.), Haworth Press, Binghamton (NY) 2002: 55-65.
35. Pope HG Jr, Gruber AJ, Hudson JI, et al. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58(10):909-915.
36. Pope HJ. Cannabis, cognition, and residual confounding. JAMA 2002; 287(9):1172-1174.
37. Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002; 287(9):1123-1131.
38. Fergusson DM, Horwood LJ, Swain-Campbell NR. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003; 33(1):15-21.
39. Patton GC, Coffey C, Carlin JB, et al. Cannabis use and mental health in young people: cohort study. BMJ 2002; 325(7374):1195-1198.
40. Iversen L. Cannabis and the brain. Brain 2003; 126(Pt 6):1252-1270.
41. Swift W, Hall W. Cannabis and dependence. In: Cannabis and cannabinoids. Pharmacology, toxicology, and therapeutic potential. Grotenhermen F, Russo E (Eds.), Haworth Press, Binghamton (NY) 2002:257-268.
42. Calhoun SR, Galloway GP, Smith DE. Abuse potential of dronabinol (Marinol®). J Psychoactive Drugs 1998; 30(2):187-196.
43. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994; 2(3):244-268.
44. Kleiber D, Soellner R, Tossmann P. Cannabiskonsum in der Bundesrepublik Deutschland: Entwicklungstendenzen, Konsummuster und Einflußfaktoren. Bonn, Federal Ministry of Health 1997.
45. Giuffrida A, Beltramo M, Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther 2001; 298(1):7-14.
46. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997; 74(2):129-180.
47. Glass M, Dragunow M, Faull RL. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997; 77(2):299-318.
48. Herkenham M, Lynn AB, Little MD, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 1990; 87(5):1932-1936.
49. Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis. Lancet Neurol 2003; 2(5):291-298.
50. Beltramo M, de Fonseca FR, Navarro M, et al. Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor. J Neurosci 2000; 20(9):3401-3407.
51. Di Marzo V, Hill MP, Bisogno T, et al. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 2000; 14(10):1432-1438.
52. Pertwee RG, Greentree SG, Swift PA. Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology 1988; 27(12):1265-1270.
53. Moss DE, McMaster SB, Rogers J. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacol Biochem Behav 1981; 15(5):779-783.
54. Navarro M, Fernandez-Ruiz JJ, De Miguel R et al. Motor disturbances induced by an acute dose of delta 9-tetrahydrocannabinol: possible involvement of nigrostriatal dopaminergic alterations. Pharmacol Biochem Behav 1993; 45(2):291-298.
55. Pryor GT, Larsen FF, Husain S, et al. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacol Biochem Behav 1978; 8(3):295-318.
56. Richter A, Loscher W. (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol 1994; 264(3):371-377.
57. Sieradzan KA, Fox SH, Hill M, et al. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001; 57(11):2108-2111.
58. Gadzicki D, Müller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999; 13(4):321-323.
59. Gadzicki D, Müller-Vahl KR, Heller D, et al. Tourette Syndrome is not caused by mutations in the Central Cannabinoid Receptor (CNR1) Gene. Am J Med Gen 2004; 127(1):97-103.
60. Singer HS. Neurobiology of Tourette syndrome. Neurol Clin 1997; 15(2):357-379.
61. Baker D, Pryce G, Giovannoni G, et al. The therapeutic potential of cannabis. Lancet Neurol 2003; 2(5):291-298.
62. Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse 1996; 22(4):382-385.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008